Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining platelet-rich plasma therapy with minoxidil was more effective in treating androgenetic alopecia in men than either treatment alone.

This study found that treprostinil, a prostacyclin analog, significantly delayed fibroblast migration from healthy donors but did not affect fibroblast migration derived from diabetic foot ulcers.

This study found that the progesterone metabolite 3α-THP increased the proliferation and gene expression of human glioblastoma cells, suggesting a role in tumor progression.

In this study, ginsenoside 20(S)-protopanaxadiol-aglycone (PPD) was shown to downregulate androgen receptor expression and inhibit tumor growth in prostate cancer cells.

In this study, PEVIII, a nanocomposite chitosan-coated vesicle containing both α-hederin and hederacoside C, demonstrated notable antibacterial activity against Pseudomonas aeruginosa in a keratitis model, showing significant lesion reduction, tissue improvement, and decreased bacterial load and inflammatory markers compared to other treatments.

This study found that platelet-rich plasma treatment significantly improved erectile function and restored neural structures in aged rats with erectile dysfunction, suggesting potential benefits for geriatric patients.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This study reported effective hair growth improvement in androgenic alopecia through subcutaneous injections of platelet-rich plasma, with observed benefits in both women and men.

Applying valproic acid on the scalp increased hair growth in men with hair loss.

This study reports that using activated platelet-rich plasma releasate in the preparation of bioengineered hair follicle germs enhanced follicular gene expression and significantly improved hair regeneration in vitro.

This study found that a combination of minoxidil, microneedling, and PRP was significantly more effective than minoxidil alone in managing androgenetic alopecia over six months.

This review analyzed 17 recent clinical trials on platelet-rich plasma for androgenetic alopecia but reports no new clinical results; the authors seek a consensus on optimal PRP use.

This study found that valproic acid promoted human hair growth by increasing β-catenin levels, suggesting it may be a potential therapeutic option for alopecia.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

Injecting platelet-rich plasma (PRP) can increase hair growth rate and density in male pattern baldness.

In this study, significant improvements in Androgenetic Alopecia were observed with both PRP and SVF therapies, with SVF showing greater effectiveness in increasing terminal and vellus hair counts.

This study found that a new hybrid compound designed from finasteride and epristeride was a potent inhibitor of 5α-reductase with a mechanism similar to finasteride.

This article discusses the potential use of platelet-rich plasma as a treatment for vitiligo, but reports no new clinical results; further investigation is needed.

In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.

Platelet-rich plasma (PRP) is an effective treatment for hair loss that involves scalp injections and requires ongoing maintenance.

This review discusses the diverse applications of platelet-rich plasma (PRP) across various medical fields and reports no new clinical results, advocating PRP as a promising therapy for future use.

This study concluded that, in male patients with mild-to-moderate androgenetic alopecia, injections of PRP prepared by an automated method combined with topical 5% minoxidil were effective and safe, showing superior clinical efficacy and patient satisfaction compared to PRP alone.

This review discusses the development and trials of finasteride for prostate cancer prevention, reporting reduced cancer prevalence but noting concerns about increased high-grade cancer incidence.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.

In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.

Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.